News

The increase in use of TKIs for patients with CML and the increase in TKI drug prices place considerable financial pressure on Medicare part-D insurers.

Ensartinib demonstrated superior efficacy to crizotinib for patients with advanced ALK-positive NSCLC in a study published in JAMA Oncology.

Compared with historical Medicare reimbursement, the Radiation Oncology Alternative Payment Model base rates provide lower reimbursement for many common treatment scenarios in community practices.

Findings from a systematic review and meta-analysis support the diagnostic importance of dermoscopic structures associated with melanoma detection and highlight the importance of the overall pattern.

Among patients with cancer, receipt of early palliative care reduced the average health system costs in the last month of life, especially through avoided hospitalizations.

Findings from a recent real-world study suggest that olaparib maintenance is both safe and effective for the treatment of BRCA-mutated recurrent ovarian cancer.

Findings from a recent study revealed that treatment-related morbidity after radiotherapy was less frequent when compared with inguinofemoral lymphadenectomy in patients with vulvar cancer, suggesting radiotherapy to be a safe treatment.

A recent study revealed that nivolumab monotherapy is a more cost-effective treatment option compared to topotecan for the third-line treatment of SCLC.

Study findings suggest no adjuvant therapy is the most cost-effective approach for postmenopausal women who receive partial mastectomy for low-risk ductal carcinoma in situ.

Findings from a recent study suggest avoiding the use immune checkpoint inhibitors in patients with advanced malignancy and poor performance status, as the outcomes are poor in this group.